Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 19;180(6):1033.
doi: 10.1016/j.cell.2020.02.028.

Reducing Treatment Burden in AMD

Rajendra S Apte  1
Affiliations

Reducing Treatment Burden in AMD

Rajendra S Apte. Cell. .

Abstract

VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including retinal fluid, a marker of disease activity, favored brolucizumab. To view this Bench to Bedisde, open or download the PDF.

PubMed Disclaimer

References

    1. Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development, Cell, 176 (2019), pp. 1248–1264. - PMC - PubMed
    1. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt U, Erfurth DM Brown A.V. Gomes, Warburton J, Weichselberger A, Holz FG, HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration Ophthalmology, 127 (2020), pp. 72–84. - PubMed
    1. Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov, 15 (2016), pp. 385–403. - PubMed
    1. Markham A. Brolucizumab: First Approval. Drugs, 79 (2019), pp. 1997–2000. - PubMed
    1. Sene A, Chin-Yee D, Apte RS. Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. Trends Mol. Med, 21 (2015), pp. 43–51. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources